Market Overview

ChemoTech operates within human oncology, focusing on the clinical and commercial development of Tumour Specific Electroporation™ (TSE).

For superficial tumours, our commercial focus includes India and selected markets in Asia, the Middle East and Africa, where there is a significant need for accessible and cost-effective cancer treatment technologies.

For the future development of TSE in deep-seated tumours, including selected indications such as pancreatic, liver, prostate and secondary bone cancer, our strategy includes clinical collaborations and development activities in selected international markets.

Unmet need in cancer care

Despite major advances in oncology, many patients continue to face limited treatment alternatives because of tumour location, advanced disease, resistance to established therapies or limited access to specialised cancer care.

ChemoTech is developing TSE to provide oncologists with an additional local treatment technology for selected superficial and deep-seated tumours, with a focus on preserving healthy surrounding tissue and supporting accessible cancer care.

Target markets

ChemoTech’s market strategy is focused on regions where the clinical need for additional cancer treatment options is significant and where cost-effective medical technology can create meaningful value for healthcare providers and patients.

Commercialisation is pursued through selected distributors, healthcare providers, cancer centres and clinical partners, supported by continued clinical development of TSE and IQwave™.

Editorial note: The existing global oncology statistics and forecasts should be refreshed separately before publication; several figures on the current page are based on 2018–2020 sources and forecasts that have already passed.

The global oncology market

The oncology market is growing every year. Costs attributable to cancer treatment in 2018 totalled $150 billion. This corresponds to an increase of 12.9 percent compared to the previous year and already in 2023 the market size is expected to exceed USD 220 billion. The Chinese market grew by 24 percent in 2018. In the United States, costs attributable to cancer treatment have doubled since 2013 and, in 2018, exceeded USD 56 billion.

Increased number of new cancer cases

In 2018, roughly 18 million new cancer cases were discovered and roughly 10 million people died of cancer in the same year. By the year 2025, the number of new cases is expected to have risen to nearly 21.5 million, which corresponds to an increase of just over 18 percent. The number of deaths is expected to increase to 11.5 million by 2025, which corresponds to an increase of approximately 20 percent.

Cost-effective and accessible cancer treatment

Developing countries account for 56 percent of new cancer cases in the world and 65 percent of all deaths in the region are caused by cancer. The fact that the deaths are significantly higher in this part of the world is probably due to a combination of late diagnoses as patients do not seek care until the disease is well advanced, as well as limited access to standard treatment and preventive care visits. We believe that with our patented technology, it is possible to provide a palliative, cost-effective, and accessible cancer treatment that has the capacity to provide these patients with effective treatment and extended life.

The countries and regions that we initially focus on are India and Southeast Asia, where we are already established in Singapore, the Philippines, Malaysia, Vietnam, and Myanmar through distributor agreements and orders received. We plan to gradually establish itself in the rest of Southeast Asia over the next two to three years.

IQwave™ can be the solution

An increasingly ageing population is also a relevant social trend for the Company. By 2050, the global population over 60 is expected to have increased to two billion. With increasing age, the number of disease cases will increase. The new medicines and the new medical technology that are introduced are in many cases very costly for healthcare, which, in combination with more and more cases of illness, puts increased pressure on the state’s expenses. Given the skyrocketing healthcare costs, healthcare providers will increasingly look for more cost-effective treatment methods. Our assessment are that IQwave™ has the conditions to meet these needs.

IQVIA. Global Oncology Trend Report 2019: Therapeutics, clinical development and health system implications
International Agency for Research on Cancer, World Health Organization. World Cancer Report 2020 (2020)
World Health Organization; Global Cancer Observatory

Get in touch

Are you interested in our products?

Our team is here to help with any questions about our products, patents or anything else you may need help with.